Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elvire Pons

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Translational Lung Cancer Research|July 10, 2023
Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinomaElvire Pons-Tostivint
Current Oncology (Toronto, Ont.)|October 27, 2022
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision MedicineElvire Pons-Tostivint, Jaafar Bennouna
Bulletin Du Cancer|March 27, 2025
[Atézolizumab in first line in patients with metastatic non-small lung cancer who are platinum-doublet ineligible]Faustine Enoch, Elvire Pons-Tostivint
La Revue Du Praticien|February 6, 2019
Breast cancer diagnostic assessmentFlorence Dalenc, Elvire Pons, Henri Roche
La Revue Du Praticien|December 6, 2018
Breast tumoursFlorence Dalenc, Elvire Pons, Henri Roché
The Breast Journal|May 16, 2017
Impact of surgery on survival in stage IV breast cancerThomas Filleron, Elvire Pons, Amélie Lusque, et al.
Translational Lung Cancer Research|March 10, 2023
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaitedMarc G Denis, Guillaume Herbreteau, Elvire Pons-Tostivint
Trends in Cancer|July 19, 2017
Targeting PI3K Signaling in Combination Cancer TherapyElvire Pons-Tostivint, Benoît Thibault, Julie Guillermet-Guibert
Molecular Cancer|January 10, 2026
Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncologyManon Chang, Thomas Papazyan, Elvire Pons-Tostivint, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2026
ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignoreElvire Pons-Tostivint, Louis Maurier, Jaafar Bennouna, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Translational Lung Cancer Research|July 10, 2023
Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinomaElvire Pons-Tostivint
Current Oncology (Toronto, Ont.)|October 27, 2022
Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision MedicineElvire Pons-Tostivint, Jaafar Bennouna
Bulletin Du Cancer|March 27, 2025
[Atézolizumab in first line in patients with metastatic non-small lung cancer who are platinum-doublet ineligible]Faustine Enoch, Elvire Pons-Tostivint
La Revue Du Praticien|February 6, 2019
Breast cancer diagnostic assessmentFlorence Dalenc, Elvire Pons, Henri Roche
La Revue Du Praticien|December 6, 2018
Breast tumoursFlorence Dalenc, Elvire Pons, Henri Roché
The Breast Journal|May 16, 2017
Impact of surgery on survival in stage IV breast cancerThomas Filleron, Elvire Pons, Amélie Lusque, et al.
Translational Lung Cancer Research|March 10, 2023
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaitedMarc G Denis, Guillaume Herbreteau, Elvire Pons-Tostivint
Trends in Cancer|July 19, 2017
Targeting PI3K Signaling in Combination Cancer TherapyElvire Pons-Tostivint, Benoît Thibault, Julie Guillermet-Guibert
Molecular Cancer|January 10, 2026
Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncologyManon Chang, Thomas Papazyan, Elvire Pons-Tostivint, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2026
ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignoreElvire Pons-Tostivint, Louis Maurier, Jaafar Bennouna, et al.
Pageof 6